NHS Dudley Health Economy Medicines Formulary
Home > 8 Malignant disease and immunosuppression > 8.1 Cytotoxic drugs > 8.1.5 Other antineoplastic drugs > Lung cancer (non-small-cell, anaplastic lymphoma kinase fusion gene, previously treated) - crizotinib NICE TAG TA296

Lung cancer (non-small-cell, anaplastic lymphoma kinase fusion gene, previously treated) - crizotinib NICE TAG TA296

1.1 Crizotinib is not recommended within its marketing authorisation, that is, for treating adults with previously treated anaplastic-lymphoma-kinase-positive advanced non-small-cell lung cancer.

1.2 People currently receiving crizotinib that is not recommended according to 1.1 should be able to continue treatment until they and their clinician consider it appropriate to stop.

https://www.nice.org.uk/guidance/TA296

 

 

Site by Devopa
© Copyright 2019 NHS. All rights reserved.